These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27104933)

  • 1. Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial.
    Strueber M; Warnecke G; Fuge J; Simon AR; Zhang R; Welte T; Haverich A; Gottlieb J
    Am J Transplant; 2016 Nov; 16(11):3171-3180. PubMed ID: 27104933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation.
    Glanville AR; Aboyoun C; Klepetko W; Reichenspurner H; Treede H; Verschuuren EA; Boehler A; Benden C; Hopkins P; Corris PA;
    J Heart Lung Transplant; 2015 Jan; 34(1):16-25. PubMed ID: 25049068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
    Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial.
    Saliba F; Duvoux C; Gugenheim J; Kamar N; Dharancy S; Salamé E; Neau-Cransac M; Durand F; Houssel-Debry P; Vanlemmens C; Pageaux G; Hardwigsen J; Eyraud D; Calmus Y; Di Giambattista F; Dumortier J; Conti F
    Am J Transplant; 2017 Jul; 17(7):1843-1852. PubMed ID: 28133906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
    Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
    Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
    Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.
    Tönshoff B; Ettenger R; Dello Strologo L; Marks SD; Pape L; Tedesco-Silva H; Bjerre A; Christian M; Meier M; Martzloff ED; Rauer B; Ng J; Lopez P
    Am J Transplant; 2019 Mar; 19(3):811-822. PubMed ID: 30125462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients.
    McNeil K; Glanville AR; Wahlers T; Knoop C; Speich R; Mamelok RD; Maurer J; Ives J; Corris PA
    Transplantation; 2006 Apr; 81(7):998-1003. PubMed ID: 16612275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
    Budde K; Lehner F; Sommerer C; Reinke P; Arns W; Eisenberger U; Wüthrich RP; Mühlfeld A; Heller K; Porstner M; Veit J; Paulus EM; Witzke O;
    Am J Transplant; 2015 Jan; 15(1):119-28. PubMed ID: 25521535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.
    de Fijter JW; Holdaas H; Øyen O; Sanders JS; Sundar S; Bemelman FJ; Sommerer C; Pascual J; Avihingsanon Y; Pongskul C; Oppenheimer F; Toselli L; Russ G; Wang Z; Lopez P; Kochuparampil J; Cruzado JM; van der Giet M;
    Am J Transplant; 2017 Jul; 17(7):1853-1867. PubMed ID: 28027625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
    Lorber MI; Mulgaonkar S; Butt KM; Elkhammas E; Mendez R; Rajagopalan PR; Kahan B; Sollinger H; Li Y; Cretin N; Tedesco H;
    Transplantation; 2005 Jul; 80(2):244-52. PubMed ID: 16041270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
    Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.
    Eisen HJ; Kobashigawa J; Starling RC; Pauly DF; Kfoury A; Ross H; Wang SS; Cantin B; Van Bakel A; Ewald G; Hirt S; Lehmkuhl H; Keogh A; Rinaldi M; Potena L; Zuckermann A; Dong G; Cornu-Artis C; Lopez P
    Am J Transplant; 2013 May; 13(5):1203-16. PubMed ID: 23433101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.